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Abstract
Randomized controlled trials (RCTs) provide strong internal validity compared with obser-
vational studies. However, selection bias threatens the external validity of randomized trials.
Thus, RCT results may not apply to either broad public policy populations or narrow pop-
ulations, such as specific insurance pools. Some researchers use propensity scores (PSs) to
generalize results from an RCT to a target population. In this scenario, a PS is defined as the
probability of participating in the trial conditioning on observed covariates. We study a model-
free inverse probability weighted estimator (IPWE) of the average treatment effect in a target
population with data from a randomized trial. We present variance estimators and compare the
performance of our method with that of model-based approaches. We examine the robustness
of the model-free estimators to heterogeneous treatment effects.
Key Words: Causal inference; External validity; Generalizability; Randomized trials
§1 Introduction
Because some researchers believe that the analytical results from randomized controlled trials
(RCTs) may not reflect the true average treatment effects that would be seen if the intervention
were implemented in a different target population (e.g., [1, 4, 30, 18]), several methods have been
proposed to account for differences between RCT and target populations. We focus on reweighting
methods such as those proposed by Cole and Stuart 2010 and Zhang et al 2015 [4, 34]. Although
these proposed reweighted average effect estimates have been promising, their characteristics have
not yet been fully developed. In this paper, we lay out a new framework for considering the
statistical properties of reweighted estimators that differentiates between a particular finite tar-
get population of interest and a more general population similar to an observational dataset. We
examine the statistical properties of several reweighted average effect estimators under different es-
timation scenarios within this framework. Further, our framework clarifies the potential to improve
variance estimation under various scenarios. We propose a new large sample variance estimator and
detail two resampling -based variance estimators for several reweighted average effect estimators
and examine their performance relative to existing variance estimation methods.
Reweighting methods attempt to extract relative benefits of both RCT and observational study
designs. The necessary conditions for making proper causal inference about treatment effects
are guaranteed in expectation by the randomization in RCTs. However, typical RCT participant
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recruitment leads some to question the validity of RCT-based results for target populations [8,
15, 4, 30, 18, 34]. Conversely, many observational studies are designed to reflect populations of
interest, either via census (as in administrative data) or by relying on probability sampling. But
these data either do not contain information about treatment or outcome at all, or possibly suffer
from hidden confounding due to participants selecting their own treatments. Neither design on its
own is sufficient for sound average treatment effect estimation in a target population.
Differences in the distribution of treatment effect modifiers between randomized trials and
target populations can lead to generalizability bias if extrapolations ignore such differences (e.g.,
[8, 30, 22, 12, 16]). The difference may be due to many possible design choices or other differences
in study characteristics, including the time and location of the study, or clinical characteristics of
the participants [13, 22, 12, 34]. In their seminal paper, Hernan, et al. (2008)[13] demonstrated
the potentially crucial impact of differences in design (and resulting analyses) by showing that if
one analyzes an observational study in a manner consistent with the design of a randomized trial,
then the previously disparate estimates may also become consistent.
While many design choices may be important, Stuart et al. (2011) [30] focus on differences
in patient characteristics across studies and propose a measure to quantify this difference that is
based on the propensity of a participant to be recruited into a trial based on his or her observed
baseline covariates. Conceptually, this propensity is identical to a propensity score employed in
traditional causal inference, defined as the conditional probability that a participant receives the
treatment of interest [26]. As such, we follow the lead of Stuart et al. (2011) [30] to call the
conditional probability of recruitment a propensity score (PS). Stuart et al. (2011) [30]go on to
propose that if the difference between the two studies is substantial, then PSs can be used to
adjust the difference in distributions between trials and target population to reduce or eliminate
generalizability bias. Cole and Stuart (2010) [29] illustrate such a PS reweighting method, showing
how standard survey sampling software designed for survival analysis can be used to estimate
generalized average treatment effects.
Several authors have implemented reweighting or calibration schemes in different but similar
contexts. For example, Hartman et al. (2015) [12]calibrate an RCT to match a target population
that received treatment already and thus estimate the population average treatment effect on the
treated. Nie et al. (2013) [22], reweight the likelihood function of a noninferiority trial (or a
historical well-controlled trial) to a similar population whose subjects can be represented by the
trial. Weiss and Varadhan (2014) [32]reweight a RCT to a target population whose treatment
modifier distributions are not overlapping, through an additional larger intermediate trial.
Corresponding to these reweighted estimators, various methods have been used to estimate their
variances, including those based on the asymptotic theory of M-estimation for inverse probability
weighted estimators (IPWEs) [21, 34], linearization approximations for survey sampling estimators
(e.g.,[20]), and bootstrap methods (e.g., [23, 7, 22, 12]). In addition, one might consider variance
estimation methods developed for weighted least square estimators, although the theory behind
this method treats the weights fundamentally differently than the other methods. Whereas weights
used in methods based on traditional probability sampling and M-estimation are seen as how many
people in the target population the subjects in the trial represent, weights used in methods for
weighted regression are treated as the inverse variance of random errors.
Different variance estimation methods also treat the calibration variables and weight models
differently. Standard linearization and other probability sampling methods, for which many sta-
tistical programming tools have built-in functions to estimate the variances, are easy to use but
do not account for the variability of estimated weights and treat the target population as known
and fixed. The M-estimation method used to obtain asymptotic variance captures the variability
of estimated weights, covariates, outcomes, and experiment design elements, but are typically not
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readily available in software. Bootstrap methods can often be designed to match the stochastic
process of the study, are straightforward to implement and can provide consistent estimators of
variance with a large number of resamples, but the algorithm is computationally expensive and
random resampling gives such estimates limited reproducability. To our knowledge, these various
approaches to variance estimation have not been compared in the generalizability setting, nor has
a large-sample variance estimation for the generalization IPWE been developed.
In addition to reweighting approaches, we note that other authors have proposed alternative
methods for correcting generalizability bias. For example, Greenland (2005)’s [9] multiple bias mod-
els and Eddy et al. (1992)’s [6] confidence profile method are general approaches typically applied
to adjust naive estimators for biases due to study design choices via parametric models. These
general approaches could, in theory, be used for the generalizability bias problem. In addition,
Kaizar (2011) [16] and Weiss and Varadhan (2014) [32] have both proposed methods for correcting
generalizability bias when observational studies are available that include both comparative treat-
ments and outcome measures. In practice, such observational data is rarely available. In addition
to these limitations, we choose to focus on reweighting methods because there is natural interest
among medical researchers in reweighting methods similar to the well-understood propensity-based
methods used for causal inference.
In particular, we develop IPWE for generalizing RCT results to a target population and propose
a variance estimation method for developed IPWE. Moreover, we examine the properties of model-
based estimators and IPW-based estimators and employ various variance estimation methods. The
performance of the average treatment effect estimators is impacted by the subjects characteristics
of RCTs and the target populations. Different variance estimation approaches may be appropriate
for different goals, eg. estimating for a fixed finite population, or for an infinite population. We
also examine the limitations of IPWE and the variance estimation approaches on the sizes of RCT
and the target population. We aim to provide guidance for choosing appropriate average treatment
effect estimators and effective variance estimation approaches under different scenarios to achieve
different goals.
§2 Methods
2.1 Population Average Treatment Effect
The population average treatment effect (PATE) has been defined throughout the relevant literature
(e.g., [3, 2, 4, 11, 12, 14, 15, 17, 16, 21, 24, 25, 26, 27, 29, 31, 34]). However, in the generalizability
problem it is important to carefully define PATE relative to the finite or infinite size of the pop-
ulation of interest. We begin this section by doing so before proceeding to define several PATE
estimators in Section 2.2. We present methods to estimate their variance in Section 2.3, including
the development of a new method and detailed descriptions of two resampling-based methods.
Based on the set up of the Rubin Causal Model, the PATE can be defined as the average
difference between the counterfactual outcomes among the subjects in the target population ([26]).
We study the average treatment effect under two cases: finite and infinite population. It is necessary
to differentiate finite and infinite populations, since the definition and estimation of PATE are
inherently different based on the attributes of these two types of populations ([19]). An example of
a finite population is all the outpatient veterans with moderate or heavy alcohol intake per day in
a given year, while if the population is extended across time to all possible veteran drinkers, then
it could be considered infinite. We can also more realistically think about an infinite population as
the distribution from which the finite population of outpatient veterans in a certain year is drawn.
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The observational data set in this situation can be conceived as drawing randomly from the finite
population which is in turn drawn from the infinite population.
The true target PATE is defined separately under the two types of populations. Let Y1i represent
potential outcome variable for person i if he/she had received treatment and Y0i represent the
potential outcome variable if he/she had received control. Should the target population be a finite
population, then we define the PATE to be:
∆∗pop = µ
∗
1 − µ∗0 =
1
N
∑
i∈Ωpop
Y1i − 1
N
∑
i∈Ωpop
Y0i
where µ∗1 and µ∗0 represent the counterfactual population averages of the outcome variables, if we
suppose everyone in the target population had received treatment or control respectively. Ωpop is
a collection of indices for the target population, and N = |Ωpop| is the size of the finite population.
Otherwise, if the target population is infinite, then we define the PATE to be:
∆pop = µ1 − µ0 = E(Y1i)− E(Y0i)
where µ1 and µ0 represent the counterfactual expected values of the outcome variables of a person
randomly drawn from the infinite population.
2.2 Estimators
The point estimators for PATE that we are interested in are the same under both types of pop-
ulation. Because a finite population can be treated as being randomly drawn from an infinite
population, an appropriate estimator for PATE under a finite population should also be appropri-
ate for PATE under an infinite population.
We focus on the performance of weighted estimators of PATE, particularly IPWEs, denoted
∆ˆIPW . Our IPWEs weight the trial to represent the target population via the formula suggested
by Stuart & Cole (2010) [4], where the weights are based on data from both the target population,
Ωpop and the trial participants, Ωtrial:
∆ˆIPW = µˆ1 − µˆ0 (1)
=
(∑
i∈Ω
TiSiŴi
)−1∑
i∈Ω
TiYiSiŴi −
(∑
i∈Ω
(1− Ti)SiŴi
)−1∑
i∈Ω
(1− Ti)YiSiŴi (2)
(3)
where Ω = Ωtrial ∪Ωpop and n = |Ω| is the size of the combined trial sample and target population,
Si is the indicator of being included in the trial, Ti is the indicator of receiving treatment, and Ŵi
is the estimated weight. Roughly speaking, subject i in the trial represents the number of subjects
with similar covariates as subject i in the target population. We postpone our discussion of how to
estimate the weights until Section 2.2.1 below. Notice that Si 6= 0 only for subjects in the trial, so
that ∆ˆIPW is based only on outcomes observed in the trial. We calculate ∆ˆIPW as the difference of
the weighted average outcomes between the treated and control group in the trial. IPWE, ∆ˆIPW in
essence is identical to survey mean based estimator, ∆ˆonlysv that is also the difference of the weighted
outcomes between two groups.
While we like the simplicity of the model-free IPW estimator, we compare it to estimators
based on a linear model of the outcome: Yi = η +X
′
iβ + Tiγ + X˜
′
iTiλ + εi, for i = 1, ..., n where
η is the intercept; β is a vector of parameters for a vector of covariates Xi; λ is a vector of
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parameters for interactions between a subset of covariates X˜
′
iand treatment; and εi for i = 1, ..., n
are independently identically distributed with mean 0.
We examine several approaches to estimating the linear model parameters. For the ordinary
least squares (OLS) estimator, the parameters are estimated through ordinary least square method.
The parameters in weighted OLS (WOLS) estimator are estimated with weights. The weights for
subject i in the trial incorporated in WOLS are the same weights, Ŵi contained in IPWEs.
For survey-based estimator, the parameters are estimated through a finite population survey
based method with weights ([20]). The weights are again the same Ŵi as in the IPWE.
Regardless of which linear model method we use, we estimate the population average treatment
effect as
γˆ +
1
N
∑
i∈Ωpop
(X˜
′
iλˆ) (4)
and denoted ∆ˆOLS , ∆ˆWOLS , and ∆ˆmodsv for the OLS, WOLS, and survey methods of parameter
estimation, respectively.
2.2.1 Construction of weights and IPWEs
We use PS ideas to construct weights. Rosenbaum & Rubin (1983) [26] proposed PSs to adjust
for systematic differences between treatment and control groups in observational studies, and thus
“balance” the distributions of the measured covariates between the two groups ([24]). We employ
PSs to make the results from RCTs generalizable to a target population. In this context, we define
a PS to be the probability of being selected into the trial (rather than the target population) given
the measured covariates ([29, 30]). Intuitively, PSs are capable of balancing the distributions of the
covariates between the trial and the target population. Thus, they can be used to weight the trial
up to some target population, such that the results from a RCT can be adjusted to be relevant to
the target population.
The weight Wi is defined as, based on the weight proposed by Stuart & Cole (2010) [29],
Wi =
{
1−P (Si=1|Xi)
P (Si=1|Xi)
P (Si=1)
1−P (Si=1) , Si = 1
0, Si = 0
Analogous to Stuart & Cole (2010)’s [29] formulation, the subjects in the trial are weighted to rep-
resent the target population, while the subjects in the target population have no weight associated
with them. The weights for the subjects in the trial consist of two parts. First, 1−P (Si=1|Xi)P (Si=1|Xi) , the
ratio of the probability of being in the target population over that of being in the trial conditional
on certain covariates, is aimed to make the weighted covariate distribution of the trial similar to the
covariate distribution of the target population. Intuitively, we first weight the trial to reflect the
entire collection of subjects, which includes the subjects both in the trial and the target population
through the inverse of P (Si = 1|Xi), and then weight to reflect only the target population with
1− P (Si = 1|Xi). Second, P (Si=1)1−P (Si=1) is the ratio of marginal probability of being selected into the
trial over that of being selected into the target population. This constant ratio standardizes the
weights, in a way that the weights sum up to the size of the trial in expectation.
We estimate the two parts involved in the weights formula separately. The second part that does
not include covariates can be estimated by an empirical ratio. That is, P (Si = 1) is replaced by the
ratio of the number of subjects in the trial to the number of subjects in the target population. The
first part is a function of the conditional probability of inclusion in the trial, P (Si = 1|Xi), which
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we call the propensity score (PS) in the generalization context. PSs can be estimated through a
logistic regression model of the probability of being in the trial with the observed covariates as
predictors, e.g. ([29]), or other nonparametric methods, e.g., ([10]).
2.3 Variance Estimation
This section discusses the variance estimation of both model-free IPWE and estimators based
on linear models. Due to the different natures of finite and infinite target populations we propose
different variance estimation methods for IPWE under different types of target population . We also
describe known approaches to variance estimation for model-based estimators and their relevance
to the two types of the target population.
2.3.1 Variance Estimation of IPWE
We differentiate the variance estimators for an IPWE under different types of populations. Under
the infinite population, the variance of an IPWE includes the variability of randomness of out-
comes, covariates in the infinite population, and constructed weights. In contrast with the infinite
population, the finite population has fixed known covariates. We do not need to account for the
variability of population covariates in estimating IPWE. Thus, it is necessary for us to use different
methods to estimate the variation of IPWE under different types of populations.
The two existing methods of variance estimators for IPWE do not explicitly distinguish the
types of the target population, but each is only appropriate for one estimation scenario. The
estimated variance of IPWE studied in Cole and Stuart, 2010 [4] was calculated with a finite popu-
lation survey based approach, which can be obtained from standard statistical computing programs
(personal communication). As for usual survey estimation practice, this variance estimation does
not incorporate variance due to estimation of weights. The study in Zhang et al., 2015 [34] men-
tions simpler formed weighted estimators and derives the corresponding variances with asymptotic
theories based on M-estimation to include the variability of the weights. Their variance estimation
procedure implicitly is more suitable for the infinite target population.
We propose variance estimators for IPWEs under both types of populations, as outlined in
Table 1. We apply M-estimation to derive the variance of IPWEs under an infinite population to
include all necessary variability, similar to the method presented in Zhang et al., 2015 [34]. We
also use a regular bootstrap method to estimate the variance, and propose two special schemes of
bootstrap to capture the variability of IPWEs with infinite target population and fixed finite target
population. We describe each in detail below.
Variance estimation method Sources of Variance Target Populatioin
Y X Weights T S Finite Infinite
Survey-design Based X X
M-estimation X X X X X X
Regular Bootstrap (RB) X X X X X X
Within Study Bootstrap(WSB) X X X X X
Within Arm Within Study Bootstrap (WAWSB) X In trial only Conditionally X
Table 1: Variance estimation of IPWE
Infinite Target Population The large sample variance proposed for IPWEs in Lunceford &
Davidian (2004) [21] inspires our derivation of the variance for our IPWEs. We apply the theory
of M-estimation on our IPWE to derive the asymptotic variance ([28]). The advantage of using
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the M-estimation method is that we can conveniently include the variability of estimating weights
via logistic regression. Specifically, the probability of being selected in the trial, for subject i,
P (Si = 1|Xi) is estimated from the observed data (Si,Xi), i = 1, .., n by the logistic regression
model with mean specification e(Xi, α) = {1 + exp(−XTi α)}−1. It is assumed that the model
for e(Xi, α) is correctly specified. Misspecification of the propensity score model may affect the
performance of IPWEs, but is beyond the scope of this study.
Based on M-estimation theory, then the asymptotic variance of the IPWE is
E(I2i )
n , where Ii is
defined as
Ii =
1
E
(
TiSi(1−ei)
ei
) TiSi(Yi − µ1)(1− ei)
ei
− 1
E
(
(1−Ti)Si(1−ei)
ei
) (1− Ti)Si(Yi − µ0)(1− ei)
ei
− 1
E
(
TiSi(1−ei)
ei
)E (TiSi(Yi − µ1)(1− ei)
ei
XTi
)
[E
(
ei(1− ei)XiXTi
)
]−1Xi(Si − ei)
+
1
E
(
(1−Ti)Si(1−ei)
ei
)E ((1− Ti)Si(Yi − µ0)(1− ei)
ei
XTi
)
[E
(
ei(1− ei)XiXTi
)
]−1Xi(Si − ei)
(4)
The asymptotic variance can be estimated by n−2
∑
i∈Ω I
2
i . The components in Ii may be estimated
from the observed data, e.g., the expectations inside Ii may be estimated by the simple arithmetic
average across the subjects, i = 1, ..., n.
In addition to the M-estimation method of deriving the variance, we use two bootstrap methods
to estimate the variance of IPWE. We repeatedly randomly draw subjects with replacement from the
combined trial and the target populations. For each bootstrap sample, IPWE is calculated. Then
the variance of IPWE is obtained by taking the sample variance among the bootstrap estimators.
With this method, the drawn trial sample sizes vary among the bootstrap samples. We also consider
a bootstrap variation to keep the resampled trial size fixed, where for each bootstrap sample, we
randomly draw trial subjects with replacement solely from the trial and draw population subjects
with replacement solely from the target population. Thus, under the infinite target population,
we have three methods to derive the variance of the estimators: One asymptotic method based on
M-estimation and two variations of the bootstrap.
Finite Target Population In addition to the standard survey sampling method, we apply a third
bootstrap method to estimate the variance of IPWEs conditioning on the trial design and fixed
target population. Because we consider the target population fixed and known, we do not resample
the subjects in the target population. For the trial participants, we maintain the trial design in
each bootstrap sample by drawing treatment observations from the treatment group randomly
with replacement and control ones from the control group in the original data set randomly with
replacement. IPWEs are calculated in each bootstrap resample and the estimated variance is the
sample variance across those IPWEs.
2.3.2 Variance Estimation of Model-Based Estimators
The methods of estimating the variance of model-based estimators have been established maturely.
The model-based estimators are constructed as a linear combination of the parameters in (4) and
the covariates in the target population. The variances of model-based estimators are computed
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based on the laws of variances of linear combinations, assuming covariates are fixed.
V ar
γˆ + 1
N
∑
i∈Ωpop
(X˜
′
iλˆ)
 = V ar([1 1N ∑i∈Ωpop X˜ ′i] [γˆλˆ
])
(5)
≈
[
1 1N
∑
i∈Ωpop X˜
′
i
]
V ar
([
γˆ
λˆ
])[
1
1
N
∑
i∈Ωpop X˜i
]
(6)
This variance estimation method for regression-based estimators is not specifically designed
for either the infinite target population or the finite target population. The set-up for defining
the V ar
([
γˆ
λˆ
])
is based on an infinite target population. Thus, the procedure for calculating the
variances of the estimated parameters in regression-based estimators is not inherently designed for
reflecting the fixed and known population. However, step (3) is derived from (2) by assuming fixed
covariates, X˜i, i ∈ Ωpop and the weights incorporated in the estimation of the variances are assumed
to be fixed and known as well. Thus, the way we estimate the variance of the regression based
estimators may underestimate the variance of the estimator if the target population is infinite. If
the fixed covariate assumption is loosened and the estimation of the weights is taken into account,
the variance estimator may be more suitable for an infinite target population. However, this is not
standard practice for regression based estimator.
This variance estimation method for survey-based estimators is specifically designed for the
finite target population. The estimated parameters in survey based estimators, γˆ, λˆ and their
variances are based on the finite population assumption. The weights of survey based estimators
contained in the estimation of V ar
([
γˆ
λˆ
])
are assumed to be fixed and known as well. Thus, this
variance estimation method using (3) are designed for the finite target population. Under infinite
population, the variances of model-based might be underestimated.
Besides the linear combination of variances method, we apply bootstrap methods to estimate
the variances of the model-based estimators as well. Following exactly the same procedures in the
two bootstrap methods described in Section 2.3.1, these variance estimation methods similarly are
suitable for the infinite target population.
§3 Simulation Study
We conduct simulations to compare the performance of IPWEs with that of model-based estimators.
We divide our exploration into two simulation studies: one is to investigate the effect of the selection
effect and heterogeneity of treatment effect in a large trial sample and the other one is to examine
the effect of sample size and proportion. Both simulations have the same set up and only differ in
choices of parameter settings.
3.1 Simulation Set-up
We set up the simulations to include a binary treatment variable (Ti = 0 or 1), one continuous
covariate (Xi) and a continuous response (Yi), for simplicity. A study indicator (Si) mimics a
realistic scenario by dividing the data into two parts — the trial data (Si = 1) and the target
population data (Si = 0).
The continuous covariate Xi is generated as a Uniform random variable between 0 and 1 for
each subject i ∈ Ω. The trial assignment Si is generated according to a Bernoulli distribution with
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the true propensity score, P (Si = 1|Xi), modeled as in a logistic regression on Xi:
P (Si = 1|Xi) = {1 + exp(−α0 − α1X)}−1 (7)
The logistic model is designed to mimic a potential treatment moderator that may be distributed
differently in the trial and the target population. In general, values of α1 close to zero produce
considerable overlapping of the conditional distributions of X across the trial and the target popu-
lation. As α1 grows in magnitude, the overlapping amount decreases. Figure 1 depicts this trend.
When α1 = 0 (left panel), there is no selection and the conditional distribution X|S = s is identical
across the two groups. As α1 increases to 8 (right panel), the two conditional distributions differ
noticeably, with most subjects in the trial and few subjects in the target population having large
values of X.
Figure 1: The conditional probability densities for X in the trial (“Trial”, dark grey) and the target
population (“Pop”, light grey) for three possible values of α1 in Equation (7).
For only the subjects i selected in the trial, i.e., Si = 1, the active treatment exposure Ti = 1
is randomly assigned to exactly half of those units in the trial; the other half are assigned to the
control treatment Ti = 0. For only the subjects in the trial as well, the response variable Yi is
generated according to
Yi = β0 + β1Xi + β2Ti + β3XiTi + εi, εi
ind∼ N(0, σ2) (8)
Our simulated data thus mimics the real world situation where individuals in the target population
may not have been treated and do not have outcome data available.
We have two simulation constructions to distinguish the types of the target population: finite
and infinite. We employ a single layer simulation set up to mimic the reality that the target
population is an infinite population. We use a double-layer simulation to mimic the reality that
the target population is a specific finite population.
3.1.1 Infinite Target Population - Single-layer Simulation
Within the single layer simulation, each Monte Carlo (MC) data set represents subjects randomly
drawn from an infinite population whose covariate distribution follows a Uniform distribution. 3000
MC data sets are generated and . In each of the MC data sets, covariate X, trial assignment S,
treatment assignment T , and the outcome Y are generated, such that the trial and the population
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subjects vary across all 3000 MC data sets.
3.1.2 Finite Target Population - Double-layer Simulation
The double-layer simulation is built on the single-layer simulation. Since under the finite target
population, the target population subjects are fixed, we add a nested layer within each single-layer
dataset that shares the same finite target population subjects, but generate 10 MC replications
of different trial subjects. For each of the 10 trial replications in the nested layer, we generate
covariate X based on the conditional distribution of the covariate, P (X|S = 1) and then generate
the treatment T and outcome Y as usual according to Equation 8. In other words, the outside
layer of the simulation contains 3000 distinct target populations, while in the nested inside layer,
there are 10 replications sharing same target population, but varying covariates and outcomes in
the trial for a total of 30000 simulated RCTs. The replications within the nested layer represent
simulated replicates of a RCT, each of which is generalized to a fixed finite target population. This
mimics the real-life situation where many trials are possible, but only one finite target population
is of interest.
3.2 Simulation Estimators
Three major types of PATEs are computed in the simulations. Regression model-based estima-
tors are the ordinary least squares estimator, ∆̂OLS and the linear model estimator including the
propensity adjustment, ∆̂WOLS in 4 of Section 2.2. The survey model-based estimator is ∆̂modsv.
The IPWEs are ∆̂IPW and ∆̂
only
sv in Equation 1 of Section 2.2. The model-based estimators not
only rely on the specification of PS model, but also that of the outcome analysis model. Thus, for
each type, we include estimators under the case of both correctly and incorrectly specified analysis
models. The superscript, cor, indicate estimators computed under the correct outcome analysis
model (i.e., the model that was used to generate the data). The misspecified analysis models have
no superscript and are calculated without the interaction term between treatment indicator and
covariate (i.e., λˆ = 0 in Equation 4), i.e., assuming no treatment heterogeneity.
As discussed in the variance estimation section 2.3, in the single layer simulation, three types
of variance estimators are calculated for each PATE estimator: the regular bootstrap, the special
bootstrap with fixed S, and a linear combination of variances for model based estimators or M-
estimation for IPWEs. In the double layer simulation, we apply the special bootstrap with fixed
S and T to estimate the variances for IPWEs and we use a linear combination of variances for the
rest of the model-based treatment effect estimators as we do in the single layer simulation set up.
3.3 Parameters for Simulation Study 1: study of effect of Selection effect and
heterogeneity of treatment effect
We examine the performance of the treatment effect and variance estimators for different amounts of
covariate overlap and treatment effect heterogeneity. As described above, α1 in Equation 7 controls
the degree of overlap between the covariate distribution of the trial and the target population or
the size of the selection effect. Thus, we vary the values of α1 to examine the performance of the
estimators as the overlap changes. Table 2 summarizes the 3 settings of αs we used and the resulting
simulated data properties. In each case, we determine α0 to achieve a pre-specified probability for
subjects to be selected in the trial. ∆p, calculated as the difference of the average of propensity
scores between the trial and the target population, measures the overlapping between the covariate
distribution of the target populations and the trial, as suggested by Stuart, et al., 2011[30].
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Type α0 α1 P (S = 1) ∆p
1 -1.39 0 0.2 0
2 -3.76 4 0.2 0.15
3 -6.62 8 0.2 0.38
Table 2: The settings of αs and resulting ∆p, the difference of the average of propensity scores
between the trial and the target population.
β3 in the outcome analysis model (Equation 8) represents the heterogeneous effect of treatment.
We also vary the value of β3 to examine the performance of the estimators for different magnitudes
of heterogeneity. The true PATE, β2 + β3E(X|S = 0), is preassigned, and β2 is determined so as
to achieve this PATE for each setting for β3. β0 is set to be 0, since it only serves as a constant.
Since β1 is only prognostic, it should not affect the performance of the treatment effect estimators
and variance estimators, β1 is constantly set to be 0.3. We select the values of β1 = 0.3, β2,
and β3 = [−1, 1] to be similar to the outcome analysis models by scaling the estimated parameter
values of the outcome analysis model in the empirical example in Section 4. Table 3 summarizes
the combinations of αs and βs we used.
Setting β2
β1 α1 = 0 α1 = 4 α1 = 8 β3
1 0.3 0.2 0.14 0.12 -1
2 0.3 0.1 0.06 0.04 -0.8
3 0.3 0 -0.03 -0.05 -0.6
4 0.3 -0.1 -0.12 -0.13 -0.4
5 0.3 -0.2 -0.21 -0.22 -0.2
6 0.3 -0.3 -0.3 -0.3 0
7 0.3 -0.4 -0.39 -0.38 0.2
8 0.3 -0.5 -0.48 -0.47 0.4
9 0.3 -0.6 -0.57 -0.55 0.6
10 0.3 -0.7 -0.66 -0.64 0.8
11 0.3 -0.8 -0.74 -0.72 1
12 0.3 -100.3 -89.38 -84.42 200
Table 3: The settings of βs across different settings of α1. In each case, values of α0 are set as in
Table 2, and the combined size is ntotal = 3000.
3.4 Parameters for Simulation Study 2: study of effect of sample and study
size
We examine how the performance of the treatment effect and variance estimators changes with
RCT and target population size. We vary the total combined size of the trial and the target
population, ntotal and the expected sample proportion, P (S = 1), to control the target population
size and the trial size. We incrementally increase the sample proportion and meanwhile decrease
the combined size, ntotal, while we keep ∆p constant. We set ∆p as 0.15, which is its value of α1 = 4
and P (S = 1) = 0.2. We keep the value of the true PATE the same as Simulation Study 1. Note
that the αs depend on ∆p and the sample proportion, while the βs depend on αs and the true
PATE. Table 4 summarizes the settings of αs and βs we used and the resulting simulated data
properties.
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Setting α0 α1 β1 β2 β3 ntotal
Sample
Proportion
Treatment
Effect
∆p
1 -3.76 4 0.3 0.14 -1 3000 20 % -0.3 0.15
13 -3.76 4 0.3 0.14 -1 1000 20% -0.3 0.15
14 -3.76 4 0.3 0.14 -1 500 20% -0.3 0.15
15 -3.76 4 0.3 0.14 -1 200 20% -0.3 0.15
16 -1.5 3 0.3 0.09 -1 500 50% -0.3 0.15
17 0.01 4.5 0.3 -0.05 -1 500 85% -0.3 0.15
18 0.56 9 0.3 -0.18 -1 500 95% -0.3 0.15
Table 4: The settings of the parameters for the study of the effect of sample size and proportions.
3.5 Measures of Performance
We compute several measures to describe and evaluate the properties of the PATE estimators for
both single and double-layer simulations. For the single-layer simulations, bias is estimated by
averaging the differences between the treatment effect estimators and the true population average
treatment effect, β2 +β3E(X|S = 0). Average standard error (Ave SE) is computed as the average
of the estimated standard deviations of the PATE estimators described in Section 2.3 across 3000
MC data sets. Monte Carlo standard deviation (MC SD) is computed as the standard deviation
of the treatment effect estimators across the 3000 MC data sets using the usual sample standard
deviation formula. MC SD is a numeric estimate of the true standard deviation of the estimators,
and thus it is treated as the measure of the true standard deviation of the estimators. Finally, two
types of 95% confidence interval coverage rates are computed across the 3000 MC data sets. We
calculate a separate confidence interval for each type of target population: infinite and finite target
population. The infinite population confidence interval is designed for covering the true PATE,
β2 + β3E(X|S = 0), while the finite population confidence interval is for covering each particular
simulation PATE, β2 + β3X¯pop.
Similar measures are computed for double-layer simulations. For the double-layer simulations,
bias is estimated by averaging the differences instead between the treatment effect estimators and
each specific simulation PATE, β2 +β3X¯pop across a total of 30000 MC data sets. Note that distinct
MC data sets have distinct X¯pop. Ave SE and two types of confidence coverage follow the same
computing procedures as in the single-layer simulations, but instead they are the averages across
the 30000 MC data sets. MC SD is the average of the 3000 standard deviation, each of which is
the standard deviation of the treatment effect estimators across the 10 replications sharing same
target population.
3.6 Simulation Results
For every combination of α and β, the estimated results and the related measures of both the
model-based estimators and IPWE are computed under the single-layer simulation construction
designed to assess properties for the infinite target population and also double-layer simulation
construction correspondingly designed for the finite target population. We first present results for
both constructions for one exploration of the effect of selection and heterogeneity, Simulation 1,
before turing to our Simulation 2 study of the effect of sample size.
3.6.1 Study of Effect of Selection and Heterogeneity of Treatment Effect
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Single-layer Simulation Results Under the single-layer simulation construction, we first look
at one generic situation which has moderate effect of selection and heterogeneity withα setting 2,
where α1 = 4 in Table 2 and β setting 3, where β3 = −0.6 in Table 3. Table 5 summarizes the
results of the corresponding simulation. Then we compare the trend of the performances of the
PATE estimators as we change the effect of selection and heterogeneity. Figures 2 summarize how
the results change with α1 and β3.
Parametric Variance Estimator Fixed S Bootstrap Bootstrap
Est Bias MC SD Ave SE
Finite
Coverage
Infinite
Coverage
Ave SE
Finite
Coverage
Infinite
Coverage
Ave SE
Finite
Coverage
Infinite
Coverage
∆̂OLS -0.166 0.082 0.082 0.48 0.47 0.082 0.47 0.47 0.082 0.47 0.47
∆̂corOLS -0.005 0.129 0.130 0.95 0.95 0.129 0.95 0.95 0.129 0.95 0.95
∆̂WOLS -0.007 0.141 0.082 0.74 0.74 0.138 0.94 0.94 0.138 0.94 0.94
∆̂corWOLS -0.005 0.142 0.082 0.74 0.74 0.140 0.94 0.94 0.140 0.94 0.94
∆̂modsv -0.007 0.141 0.139 0.95 0.94 0.138 0.94 0.94 0.138 0.94 0.94
∆̂cormodsv -0.005 0.142 0.139 0.94 0.94 0.140 0.94 0.94 0.140 0.94 0.94
∆̂onlysv -0.006 0.141 0.140 0.95 0.95 0.139 0.94 0.94 0.139 0.94 0.94
∆̂TIPW -0.006 0.141 0.140 0.95 0.94 0.140 0.94 0.94 0.140 0.94 0.94
Table 5: Simulation results for (α0, α1) = (−3.76, 4) and β3 = −0.6 under single-layer simulation
set-up. See Section 3.2 for a description of the estimators and Section 3.1 for a description of the
summaries.
Table 5 clearly shows the difference of bias across all the estimators. Without knowing the
correctly specified analysis model, the unweighted regression model-based estimators ∆̂OLS has the
largest bias among all the treatment effect estimators. The model-based estimators with correct
analysis model have almost the same amount of bias and have less bias than the model-based
estimators with incorrect analysis model do, which have consistent amount of bias also. The bias
of the IPWEs is between the model-based estimators with correctly specified analysis model and
those with incorrectly specified model.
MC SD column reflects the true variability of each PATE estimators. ∆̂OLS has the smallest
MC SD, but with the largest bias, we practically do not prefer it. Thus, we do not discuss it
regarding the other property comparison. With correct analysis model, ∆̂corOLS has the smallest
standard deviation. The rest of the model-based PATE estimators and IPWEs have similar MC
SD.
Table 5 compares the performances of the variance estimation methods: Parametric M-estimation,
survey-based and model-based linear combination estimators, Fixed S bootstrap, and regular boot-
strap methods as described in Section 2.3. In this single-layer simulation construction, the standard
deviation estimate of IPWEs from the Parametric methods and the two bootstrap methods are all
slightly smaller than, but very close to the “true” standard deviation, MC SD, except for the WOLS
estimators, ∆̂WOLS and ∆̂
cor
WOLS . In this case, the linear combination of variances method severely
under-estimates the true standard deviation. This is not entirely surprising, since the weights in a
weighted regression have a variance interpretation quiet different from population representation.
The finite and infinite population coverages are almost the same for each variance estimation
method across the treatment effect estimators. There are two types of estimators for which the
coverage is poor, WOLS under correct or incorrect analysis model with Parametric variance meth-
ods. With under-estimates of the variances, the corresponding coverages are below the nominal
level. All the other intervals have coverages that achieve or nearly achieve 95%.
The same comparative performance hold across all the αs and βs settings.
Because it has good properties and is robust to model mis-specification, we focus on the IPWEs.
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Figure 2: The first row of the panel is bias and the differences between Ave SE and MC SD across
β3 values and α1 = 0, 4, and 8; the second row of the panel is two types of 95% coverage rates of
IPWE across β3 values and α1 = 0, 4, and 8.
Both heterogeneous effect of treatment (as determined by β3) and the similarity between the trial
and the target population covariate distributions (as determined by α1) determine the scale of the
bias of the IPWE, as shown in the left panel of Figure 2. If there is a considerable amount of
overlap between the covariate distributions of the trial and the target population (i.e., α1 = 0),
the trial can fully represent the target population through weighting by IPWE, and thus the bias
of the IPWE is pretty small. Furthermore, if β3 = 0, there will be no heterogeneity and thus no
bias, regardless of the values of the other parameters. As α1 increases or the absolute value of β3
increases, the absolute value of the bias of the IPWE increases. (Note that the deviations from
smooth lines in this figure are due to MC variation.) We expected to see these trends. If there is
not enough overlap between the covariate distributions (as for large α1), some part of the target
population is unable to be well-represented by the trial through weighting and thus the IPWE is
biased. If paired with large heterogeneous treatment effect, then the bias may be worse. We can
clearly see that the absolute value of the bias of IPWE climbs up as β3 increases. This pattern is
clearest for α1 = 8, but is also present for smaller α1 = 4.
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Figure 3: Plot with (α0, α1) = (−6.62, 8) and positive heterogeneous effect. The trial subjects most
likely are assigned with large scale of covariates, while the target population subjects most likely
have small covariates. With positive heterogeneous effect, subjects with large covariates tend to
have large treatment effect.
The heterogeneous effect of treatment and the similarity between the trial and the target pop-
ulation also indicate the sign of the bias of the IPWE. As shown in the left panel of Figure 2, with
positive and large heterogeneous treatment effects, the subjects who have large covariates tend
to have large treatment effects. Figure 3 depicts these phenomena for simulation setting 11 with
β3 = 1 and α1 = 8. Because α1 is positive, most of the mass for the density of X in the trial is for
greater values than most of the mass for the target population. Because β3 is positive, the treat-
ment effect (the difference between the solid and dotted lines) is also larger for these large values
of covariate X. As α1 increases, part of the target population, which are assigned with smaller
covariates may not be represented by the trial. In other words, the weighted trial only represents
most of the subjects in the target population with large covariates. Thus, as positive heterogeneous
treatment effect β3 increases, the bias increases in the positive direction. Vice versa, a negative
heterogeneous treatment (negative β3) equally means that the subjects with large covariates may
have small treatment effects. Then the average population treatment effect is estimated among the
population who intend to have large covariates. Thus, the treatment effect estimated by the IPWE
might be smaller than the true PATE, or negatively biased.
The trend of various variance estimation methods depend on the parameter values. The per-
formance of the M-estimation variance method is related to the value of α1, which controls the
similarity of the covariate distributions of the target population and the trial. With closer to 0
α1, there is a considerable amount of overlapping between the target population and the trial and
there is almost no difference between M-estimation estimates of IPWE and its corresponding MC
SD as shown by the red line in the top right figure of Figure 2. That is, the variance estimate is
approximately unbiased. As α1 increases, the bias increases as well and the M-estimation method
underestimates the “true” variability of IPWE, which is shown most clearly by the blue line in
the top right figure of Figure 2. The heterogeneous effect, β3 does not affect the accuracy of the
M-estimation variance estimation method.
The two bootstrap methods, the regular one and the special one with fixed the trial indicator
S have similar performance. Across all the scenarios, the estimated standard deviations from both
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bootstrap methods are almost identical and they are very similar with the parametric estimation
results, except for the estimates for the weighted regression PATEs. In that case, the bootstrap
methods perform better than the Parametric method.
The trends in bias and SE estimator accuracy imply the trends we see in CI coverage. Under
the situation that the target population and the trial is similar enough (i.e. α1 close to 0 as in the
highest two lines in Figure 2), the 95% confidence interval for the IPWE captures both the infinite
population average treatment and the specific target population average treatment nearly at the
nominal level. Since there is little difference in the performance of the variance estimators, there is
also almost no difference among the coverage rates for all three variance estimation method for the
IPWE. As α1 increases, the coverage rates apparently move below 95% as shown by the differences
between the three lines in the center and right panels of Figure 2. This is not surprising since the
bias increases and the variance estimation methods perform poorly as α1 increases.
Double-layer Simulation Results Using double-layer simulation set-up, similar as single-layer
simulation analysis, we first look at one generic situation which has moderate effect of selection and
heterogeneity withα setting 2, where α1 = 4 in Table 2 and β setting 3, where β3 = −0.6 in Table
3. Table 6 summarizes the results of the corresponding simulation. Then similar to the comparison
of results across all scenarios in the single-layer construction, we examine the performances of the
treatment effect estimators in the double-layer construction. Both the magnitudes and the trends
we showed regarding the bias in the singl-layer construction are maintained in the results of the
double-layer coustruction. We compare the trend of the performances of the PATE estimators as
we change the effect of selection and heterogeneity. Figures 4 summarizes how the results change
with α1.
Est Bias MC SD Ave SE
Finite
Coverage
Infinite
Coverage
∆̂OLS -0.166 0.080 0.082 0.48 0.48
∆̂corOLS 0.001 0.127 0.130 0.95 0.95
∆̂WOLS -0.002 0.139 0.082 0.74 0.74
∆̂corWOLS 0.001 0.140 0.082 0.73 0.73
∆̂modsv -0.002 0.139 0.139 0.94 0.94
∆̂cormodsv 0.001 0.140 0.139 0.94 0.94
∆̂onlysv -0.001 0.139 0.140 0.94 0.94
∆̂BootstrapIPW -0.001 0.139 0.139 0.94 0.94
∆̂M−estIPW -0.001 0.139 0.140 0.94 0.94
Table 6: Simulation results for (α0, α1) = (−3.76, 4) and β3 = −0.6 under double-layer simulation
set-up. See Section 3.2 for a description of the estimators and Section 3.1 for a description of the
summaries.
Bias column in Table 6 shows the difference of bias across all the estimators. The comparison
between the PATE estimators is the same as that in Table 5. Except that, IPWEs has almost
the same bias as the model-based estimators with correct analysis model. In terms of the true
variability of the PATE estimators, ∆̂corOLS has the smallest MC SD as expected and the rest of the
PATE estimators have similar variability.
Ave SE of the model-based PATE estimators is computed with survey-based and model-based
linear combination estimators; Ave SE of IPWEs is measured with survey-based linear combination
16
method, parametric M-estimation, and the special bootstrap method. The Ave SE of all the
model-based PATE estimators is very similar to their corresponding MC SD, except WOLS, which
is same pattern as we see in the Table 5. All the three variance methods for IPWEs perform
resemblingly and approximately equal to the MC SD. The special bootstrap method estimates
the variances for IPWEs well. Thus, we speculate that this bootstrap method may estimate the
variances for the model based treatment effect estimators properly as well. However, we do not
show the corresponding simulation results in this paper.
Consistent with the single-layer construction, the finite and infinite population coverages are
almost the same for the PATE estimators. Almost all of the coverage rates of the PATE estimators
reach the nominal level, except WOLS. Note that ∆̂OLS due to the large bias is not discussed here.
Figure 4: Bias and two types of 95% coverage rates of IPWE across β3 values and α1 = 0, 4, and 8.
The same comparative performance of the bias, Ave SE, and the coverage rates holds across
the α and β settings. Moreover, the trend of IPWEs shown in the Figure 4is similar to the Figure
2.
Figure 5: The results of the bias of M-est and the special bootstrap method compared with MC SD
for (α0, α1) = (−3.76, 4). The left panel covers the extreme case of β3 and the right panel zooms
in to the range of β3, (-1,1).
Across the settings in Table 3 with moderate treatment heterogeneity, the M-estimation stan-
dard deviation estimates are only slightly larger than the special bootstrap standard deviation
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estimates and the true SD, even though the M-estimation method is designed for accounting for all
the sources of variability. As shown in Figure 5, the blue line of M-estimation standard deviation
fluctuates above 0 and the green line of the special bootstrap estimates. However, as β3 increases
dramatically, the estimates from the M-estimation method clearly exceeds the bootstrap estimates
outstandingly and thus overestimates the standard deviation of IPWEs strikingly, as shown by the
differences between the two types of lines of the left panel in Figure 5.
The trend regarding the two types of coverage rates in the double-layer set up is also identical
to that in the single-layer set up. For α1 close to 0, the 95% confidence interval for the IPWE
captures both the infinite population average treatment and the specific target population average
treatment nearly at the nominal level, as shown by the highest two lines in the center and right
panels of Figure 4. However, the coverage degrades for larger magnitudes of α1. The two types
of coverage rates for the IPWEs are almost identical across all the scenarios as shown in Figure
4. This trend is as we expected, since the large sample sizes would result in minimal differences
between the finite- and infinite-population PATE.
3.6.2 Study of Effect of Sample Size and Proportion
We further conduct a second simulation study to examine the effect of sample size and proportion
on the performance of the PATE estimators, especially IPWEs and the corresponding variance
estimation methods. The variance estimation methods particularly heavily rely on the asymptotic
environment as shown in Simulation Study 1. Thus, we follow the framework in the Simulation
Study 1 to probe into the effect of sample size and proportion in both single-layer and double-layer
constructions.
Single-layer Simulation Results Similar to Simulation Study 1, same measures are taken in
each simulation with parameters as shown in Table 4. We examine the performance of the PATE
estimators across the settings 13-18 based on Bias and MC SD. The patterns of the performance
among the PATE estimators are similar to that in Simulation Study 1, except that the scale of Bias
and MC SD increases as ntotal decreases. Table 8 shows the Bias and MC SD of the PATE estimators
under one setting 15. As exhibited in Simulation Study 1, under realistic situation without prior
knowledge of the outcome analysis model, IPWEs outperform the model-based estimators with
smaller bias and moderate variability. Thus, we concentrate on the performance of IPWEs, i.e.
∆̂onlysv and ∆̂IPW , and the corresponding variance estimation methods for the rest of this section.
Est Bias MC SD
∆̂OLS -0.286 0.324
∆̂corOLS -0.008 0.578
∆̂WOLS -0.079 0.519
∆̂corWOLS -0.007 0.636
∆̂modsv -0.079 0.519
∆̂cormodsv -0.007 0.636
∆̂onlysv -0.042 0.552
∆̂IPW -0.042 0.552
Table 7: Simulation results for (α0, α1) = (−3.76, 4) and ntotal = 200 under setting 15 in Table 4.
The bias and the variability (MC SD) of IPWEs dramatically increase, as solely the combined
size, ntotal decreases across settings 1,13,14, and 15 summarized in Table 4, shown on the top panel
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in Figure 6. As we shrink the size of ntotal, we obtain less information from the trial to infer the
PATE. Thus, the bias and the variability increases as well. However, as we increase the sample
proportion from setting 16 to setting 18 summarized in Table 4, we gain more information from
the trial to infer the PATE and thus the bias and the variability of IPWEs decrease nearly to the
level before(setting 1).
Figure 6: The first row of the panel is bias and MC SD of IPWEs; the second row of the panel is the bias
of the standard deviation estimation methods, which include the M-estimation, Fixed S bootstrap, regular
bootstrap, and the linear combination of the variances using survey sampling method and 95% infinite
coverage rates of IPWE across simulation settings 1 and settings 13-18 under single-layer simulation set up.
The variance estimation methods of ∆̂onlysv and ∆̂IPW including the parametric variance esti-
mation methods and the bootstrap methods underestimate MC SD substantially as ntotal drops.
The parametric variance method (M-estimation) of ∆̂IPW deviates most, since it heavily relies
on the asymptotic theories, while the bootstrap methods deviates least. However, as the sample
proportion climbs up, with more trial information retained, all the methods estimate closely to MC
SD as shown in lower left panel of Figure 6. The bootstrap methods, i.e. the regular bootstrap
and the fixed S bootstrap of ∆̂onlysv and ∆̂IPW return similar estimates, so the lower left panel of
Figure 6 only includes the bootstrap results of ∆̂IPW .
The finite coverage rates and infinite coverage are almost the same from setting 13 to 18. The
coverage rates declines as ntotal and then raise up to the nominal level as the sample proportion
increases.
Double-layer Simulation Results The performance of IPWEs behave similarly as single-layer
simulations. The decreasing ntotal drags down the performance of IPWEs, but the increasing sample
trial improves the performance of IPWEs as shown in top panel of Figure 7.
The variance estimation methods we consider here are the parametric variance estimation
method of ∆̂onlysv , the special bootstrap for ∆̂IPW and its M-estimation method. Those methods
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Figure 7: The first row of the panel is bias and MC SD of IPWEs; the second row of the panel is the bias of
the standard deviation estimation methods, which include the M-estimation, the special bootstrap, and the
linear combination of the variances using survey sampling method and 95% finite coverage rates of IPWE
across simulation settings 1 and settings 13-18 under double-layer simulation set up.
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again insufficiently estimate the variability of IPWEs with ntotal small, but the special bootstrap
and the parametric variance estimation method of ∆̂onlysv are more reliable than the M-estimation,
which deviates the most as shown in lower left panel of Figure 7. With large proportion of sample
size all the variance methods estimate the variability well. Finite coverage rates are still almost the
same as infinite coverage rates. Thus, Figure 7 only shows the finite coverage rates and the trend
is similar to those in single-layer simulation.
IPWEs perform poorly as ntotal decreases, especially the variance estimation methods. The
performance of the M-estimation and the bootstrap methods depend on the asymptotic theories.
Thus small ntotal breaks and drags these methods down. However, when there are relatively large
size of trials, the variance estimation recovers from the small size of ntotal and thus, perform well.
In terms of the simulations, as ntotal decreases, we drop several MC data sets due to insufficient
target population size.
§4 Empirical Example: Prevention and Treatment of Hyperten-
sion Study
In this section, we demonstrate the use of IPWE with variances estimated via M-estimation and
the special bootstrap method on a real empirical example. We generalize the results of a ran-
domized trial of an alcohol moderation treatment on blood pressure among moderate or heavy
alcohol veteran drinkers with hypertension to this subset of the U.S. population. We obtain
trial data from Prevention and Treatment of Hypertension Study (PATHS) sponsored by the Na-
tional Heart, Lung, and Blood Institute (NHLBI). The detailed design, inclusion criteria, and
the trial original goal can be found at https://biolincc.nhlbi.nih.gov/studies/paths/. We extract
the population data from the National Health and Nutrition Examination Survey (NHANES) at
https://wwwn.cdc.gov/nchs/nhanes/.
PATHS
(size = 616)
NHANES
(size = 83)
Age, year
(SD)
58.9
(10.6)
53.2
(13.4)
Baseline DBP, mmHG
(SD)
86.6
(5.2)
81.9
(7.0)
Table 8: Baseline characteristics in PATHS and NHANES. Values are mean (SD).
The PATHS trial in total includes 616 subjects, recruited from 1989-1994. The subjects were
randomized either to an alcohol reduction treatment or to a control condition. Based on Cushman,
et al ’s [5] literature review, the statistically significant treatment modifiers affecting the change
of DBP are age and the baseline measure of DBP before the treatment, even though additional
potential treatment modifiers are included in the PATHS, e.g., body mass, sodium and potassium
excretion, weight, and so on ([5, 33]). While the study of Cushman et al. (1998) [5] considers several
outcome measures, e.g. systolic blood pressure and diastolic blood pressure(DBP), we only focus
on one of the main problems the study discussed, whether DBP is reduced in the 6 months after
the treatment. Table 5 of Cushmanet al.’s study (1998) [5] shows that the intervention group had
a 0.3 mm Hg greater reduction in DBP at the 6th month compared with baseline DBP measures
with standard error 0.6 mm Hg controlling for the confounding factors mentioned above. Thus,
on average, there was little evidence of an effect of intervention. However, because of potential
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treatment heterogeneity, a significant difference could appear in a different population.
The population data we select is obtained from NHANES 1999-2000 Questionnaire Data, the
year nearest to the study year of PATHS. We subset the population data based on exactly same
inclusion and exclusion criteria of PATHS study to ensure the similarity between the trial and
the target population. We end up with only 83 subjects. These 83 population subjects can be
considered as either the specific finite target population or a target population randomly drawn
from the infinite population. For the purpose of demonstrating our method, we consider the
finite population to be the outpatient veteran survey participants who reported moderate or heavy
alcohol intake per day in 1999− 2000. The corresponding infinite population can be defined as all
possible moderate or heavy veteran drinkers across U.S.with characteristics similar to the survey
participants. Table 8 summarizes baseline characteristics in PATHS and NHANES.
Figure 8: The distributions of PS in the trial and the target population.
We compute ∆p to measure the similarity of the covariate distribution between the target
population and the trial. Figure 8 exhibits the distributions of PS in the trial and the target
population, with ∆p = 0.164. There is considerable overlap between the distribution of the target
and the population.
Estimate SE 95% CI (mm HG)
RCT (PATHS) 0.300 0.600 (-0.88,1.48)
Infinite pop M-est 0.188 0.807 (-1.39, 1.77)
Finite pop bootstrap 0.188 0.756 (-1.29, 1.67)
Table 9: Baseline characteristics in PATHS and NHANES. Values are mean (SD).
We apply IPWE and the corresponding variance estimation methods, M-estimation and the
special bootstrap to generalize the trial results of PATHS (as shown in the first line in Table 10) to
the target population, NHANES. Although NHANES is a complex sample survey, we chose not to
incorporate the survey design in the weight estimation, as this is beyond the scope of our proposed
and comparative methods. We calculate ∆̂IPW as 0.188 mm HG of DBP with estimated standard
deviation using M-estimation method, 0.807 mm HG. If we are interested in the average treatment
effect for all possible moderate or heavy veteran drinkers across U.S. and also across years, the 95
% confidence interval for the average treatment effect is -1.39 to 1.77 mm HG. Thus, the alcohol
reduction treatment may not be effective on hypertension among U.S. veterans. We apply the
special finite population bootstrap method to estimate the standard deviation of ∆̂IPW , 0.756 mm
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HG, which is slightly smaller than the results of the M-estimation method. If we only concentrate
on 1999 U.S. moderate or heavy veteran drinkers, the confidence interval for the average treatment
effect is between -1.29 and 1.67 mm HG. The results are summarized in Table 10.
We also calculate the model-based estimators described in Section 2.2 and 3.2, including OLS,
WOLS, and survey based estimators to compare with IPWE. For those model-based estimators,
we choose to use a linear combination of variances method to estimate the standard deviation. We
decide the outcome analysis model as
Y = ρ0 + ρ1Age+ ρ2BaselineDBP + ρ3Trt+ ρ4Trt ∗BaselineDBP +  (9)
Y is the change of DBP at 6th month compared with baseline DBP and  represents the inde-
pendent normal random errors. We do not add another interaction term between Trt and Age
due to its extreme small effect size. Then the model-based PATE estimators shares the form,
ρˆ3 + ρˆ4BaselineDBP pop. The results are summarized in Table 10.
Estimate SE 95% CI (mm HG)
∆̂WOLS 0.512 0.618 (-0.70, 1.72)
∆̂modsv 0.512 0.931 (-1.31, 2.34)
∆̂onlysv 0.188 0.806 (-1.39, 1.77)
Table 10: Baseline characteristics in PATHS and NHANES. Values are mean (SD).
Compared with the model-based estimators, we recommend to choose IPWEs to generalize the
trial results to the target population. The results we have in Table 10 exhibit a similar pattern
in Table 5 and 6. Compared with our simulation scenarios, ∆p lies between the second (α1 = 0)
and the third scenario (α1 = 4) in Table 2 and much closer to the second scenario with ∆p = 0.15.
∆̂OLS presumably should have largest bias without prior knowledge of the analysis model and in
Table 10 it has inconsistent estimates compare with other estimators. ∆̂WOLS and ∆̂modsv with
same analysis model have similar estimates for PATE, while the estimated standard deviation of
survey based estimator is larger than WOLS as expected. ∆̂onlysv and ∆̂IPW have similar estimated
standard deviation. Without any knowledge of the outcome analysis model, IPWEs are the safe
choice to use. Furthermore with large sample proportion, approximately 88% and moderate size
of ntotal = 699, we have more confidence to prefer ∆̂
only
sv and ∆̂IPW to the other model-based
estimators for the two types of the target population.
The generalization to the target population is necessary if the researchers try to implement
the alcohol moderation treatment in PATHS to some target population, even though the bias of
IPWEs might be a concern. The plot 8 clearly shows that the distributions of PSs are quiet different
between the PATHS trial and the target population. Thus, with moderate size of ∆p, the results
of PATHS need to be tuned to suit for the target population. However, the distribution of the
target population is more left skewed than that of the trial. The non-overlapping part might arise
the concern of the bias of the IPWEs, but based on the simulation studies we conduct, IPWEs are
suggested to use and they should have promising coverage rates of the true PATE.
§5 Discussion
In our study, we concentrated on reweighing methods, first carefully defining the parameter of
interest, then studying different model-based average treatment effect estimators and IPWEs to
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weight the trial results to represent the target population, and proposing several variance estima-
tion methods for IPWEs. In particular, we proposed a new variance estimator and develop several
bootstrap-based variance estimation methods for IPWEs under different types of target popula-
tions. We conducted two simulation studies to examine the properties of the PATE estimators and
the proposed variance estimators under various magnitudes of selection and heterogeneity effect
sizes and different sample size situations. We also demonstrated these methods in a realistic data
example.
We define PATE for different types of populations, the infinite and finite target population.
We apply single-layer simulation construction to assess the properties of the PATE estimators
and their corresponding variance estimation for the infinite target population and use double-
layer simulation construction for the finite target population. The trend of the performances of
the PATE estimators in the single-layer simulation construction is similar to that in the double-
layer simulation construction. The variance estimation methods behave differently in these two
simulation constructions, which is summarized later.
Our study can provide guidance to practitioners as to which PATE estimator to use in specific
data situations. The performance of the PATE estimators depends on the similarity between the
trial and the target populations, the size of the heterogeneity of the treatment effect, the size of
the populations, and the prior knowledge of the analysis model. If the target population covariate
distribution is completely identical with the trial’s, then weighted or unweighted, model-based or
IPWE all perform well. It is not necessary to weight the trial results for a target population and
it is safe to apply the trial results directly to the target population. As there is less overlap of the
covariate distribution between the target population and the trial, i.e., ∆p increases up to 0.38,
then we concern the generalization results through any weighted PATE estimator due to large bias
and low coverage rates. With ∆p less than 0.38, IPWEs perform similarly to the other model-
based estimators with similar bias. With low ntotal, IPWEs outperform the other model-based
estimators with smaller bias. As ntotal drops between 200 and 500, IPWEs are concerned to use
due to low coverage rates. With high sample proportion, IPWEs can perform as well as if ntotal
is large. However, even under the case of high sample proportion, i.e., 95%, with low ntotal, i.e.,
between 200 and 500, IPWEs should be used with caution due to slightly low coverage rates. With
ntotal ≤ 200, IPWEs are not suggested due to unstable computation results.
Different variance estimation methods are suggested for the infinite and the finite target popu-
lation. If we deal with the infinite target population, as ∆p is between 0 and 0.15, the parametric
variance estimation method, the regular bootstrap, and the fixed S bootstrap all provide similar
results closer to the true variability for all the PATE estimators, except the weighted OLS. For the
weighted OLS, the boostrap methods outperform the parametric method. As ∆p increases up to
0.38, all the variance estimation methods underestimate the true variability. If the target popu-
lation is finite, as ∆p is between 0 and 0.15, the parametric variance estimation method and the
special bootstrap both provide similar results closer to the true variability for the corresponding
PATE estimators, except the weighted OLS, for which the boostrap method is recommended. As
∆p increases up to 0.38, all the variance estimation methods underestimate the true variability.
Especially for IPWEs, with extreme large size of the heterogeneity of the treatment effect, the
special bootstrap provides better estimates than the M-estimation.
The sample size and sample proportions affect the performance of variance estimation meth-
ods. No matter the types of the target population, as ntotal decreases between 200 and 500, all
the variance estimation methods severely underestimate the true variability of the PATE estima-
tors. Associated with the increasing sample proportion to 95%, the variance estimation methods
provide better estimates, but still the parametric method does not estimate the variability of the
weighted OLS well. Especially for IPWEs, the bootstrap methods are always recommended. The
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M-estimation breaks easily as ntotal drops. Even with high proportions, i.e., 95%, if combined
with low ntotal, i.e., lower than 500, we should be cautious with the performance of the variance
estimation methods.
Now we can combine the findings of the PATE estimators with the performance of the cor-
responding variance estimation methods. Under moderate overlap of the covariate distributions
between the trial and the target population, i.e. ∆p ≤ 0.15 and large sample size, if the target
population is infinite, the weighted OLS with bootstrap methods and the survey based weighted
estimators with either the parametric method or the boostrap method perform as well as IPWE
with either bootstrap methods or the parametric variance estimation method. All of them have
smaller bias and the coverage rates closer to the nominal level. Under same scenarios, if the target is
finite, then the survey based weighted estimators with the parametric variance estimation method
and IPWEs with either the parametric methods or the bootstrap methods outperform than the
others. Under other extreme cases, IPWEs with either bootstrap methods (ntotal is low) or the
parametric methods outperform than the others with smaller bias and higher coverage rates.
Limitations of the IPWEs and the proposed variance methods appear under the scenarios of
extreme dissimilarity between the populations or small trial size, and of extreme large heterogene-
ity of treatment effect. First, when there is considerable lack of overlap between the covariate
distribution of the target population and the trial (large ∆p) or there is a small trial, the model-
based treatment effect estimators and IPWEs cannot recover the true PATE from the trial results
successfully. Under those situations, without prior knowledge of the outcome analysis model, the
PATE estimators have large bias and low coverage rates for the PATE regardless of the types of the
target population and the variance estimation methods. Since the trial cannot represent some part
of the target population, the weighted treatment effect estimators perform poorly. The variance
estimation methods including the M-estimation and the bootstrap methods heavily rely on the
asymptotic theories which require large sample size. When the sample size shrinks, those variance
estimation methods collapse.
Second, with large heterogeneity of treatment effect the model-based treatment effect estimators
and IPWEs also perform poorly with large bias. But, since the methods overestimate the variance,
IPWEs end up with higher coverage rates for the true PATE regardless of the types of the target
populations. However, even though under these extreme scenarios, compared with the model-based
treatment effect estimators, IPWEs still outperform them.
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